Literature DB >> 21692978

Novel insights into the development of atherosclerosis in hemophilia A mouse models.

D R Fabri1, E V de Paula, D S P Costa, J M Annichino-Bizzacchi, V R Arruda.   

Abstract

BACKGROUND: Cardiovascular diseases in aging people with hemophilia (PWH) represent a growing concern. The underlying hypocoagulability probably provides a protective effect against acute thrombus formation, but the limited data available show no preventive effect against the development of atherogenesis in PWH. Atherosclerosis-prone mice are attractive tools for the study of atherosclerosis development, and may provide insights into disease progression in PWH.
METHODS: Severe hemophilia A (factor VIII-deficient [FVIII(o)]) mice were crossed with mice lacking apolipoprotein E (ApoE(-/-)) or mice lacking the LDL receptor (LDLR(-/-)), and then compared to hemostatically normal littermate controls. After mice had received atherogenic diets for 8, 22 or 37 weeks, atherosclerotic lesion size and phenotypic characterization were analyzed in the aortic sinus and whole aortas.
RESULTS: ApoE(-/-)/FVIII(o) mice showed a time-dependent protective effect against the development of atherosclerosis, beginning after 22 diet-weeks and persisting to 37 diet-weeks in both the aorta sinus and whole aorta as compared with ApoE(-/-) mice. Notably, the FVIII deficiency did not influence the progression of atherosclerosis in the FVIII(o)/LDLR(-/-) model as compared with controls at early or late time points.
CONCLUSIONS: Hypocoagulability ameliorates vascular disease in the ApoE-deficient model in a lipid-independent manner. Interestingly, FVIII deficiency did not affect the development of atherosclerosis in LDLR(-/-) mice. In contrast to the ApoE model, the LDLR model resembles the lipid profile that is commonly observed in humans with atherosclerosis. These findings, to a certain extent, support the notion of atherosclerosis development in the complete absence of FVIII.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692978     DOI: 10.1111/j.1538-7836.2011.04410.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

Review 1.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

2.  The Clot Thickens in Atherosclerosis.

Authors:  Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03       Impact factor: 8.311

Review 3.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

4.  Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.

Authors:  Reut Shnerb Ganor; Dror Harats; Ginette Schiby; David Gailani; Hanna Levkovitz; Camila Avivi; Ilia Tamarin; Aviv Shaish; Ophira Salomon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-21       Impact factor: 8.311

Review 5.  Cardiovascular disease in hereditary haemophilia: The challenges of longevity.

Authors:  Susan Shapiro; Gary Benson; Gillian Evans; Catherine Harrison; Sarah Mangles; Mike Makris
Journal:  Br J Haematol       Date:  2022-02-21       Impact factor: 8.615

6.  Novel Lesional Transcriptional Signature Separates Atherosclerosis With and Without Diabetes in Yorkshire Swine and Humans.

Authors:  Stefan Haemmig; Ali Hashemi Gheinani; Marina Zaromytidou; Gerasimos Siasos; Ahmet Umit Coskun; Michelle A Cormier; David A Gross; A K M Khyrul Wara; Antonios P Antoniadis; Xinghui Sun; Galina K Sukhova; Fred G P Welt; Ioannis Andreou; Carl Whatling; Li-Ming Gan; Johannes Wikström; Elazer R Edelman; Peter Libby; Peter H Stone; Mark W Feinberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.